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Antibiotic drug development remains a major challenge with few candidates in 
clinical development. Ramizol, a first-in-class styrylbenzene antibiotic, is under 
development for the treatment of Clostridium difficile associated disease. Here, we 
investigate the in vitro antibacterial activity of Ramizol in comparison to fidaxomicin, 
vancomycin and metronidazole against 100 clinical isolates of C. difficile by the broth 
microdilution method. We show there is no apparent impact of ribotype, toxin-
production, or resistance to fidaxomicin, vancomycin or metronidazole on the activity 
of Ramizol. Moreover, we show Ramizol has a narrower MIC range translating to 
potentially better control over the therapeutic dose. Together, these results support the 















Antibiotic resistance is a global health crisis exacerbated by a deficiently unhealthy 
antibiotic drug pipeline. By 2050, antibiotic drug resistance is predicted to overtake 
cancer as the leading cause of death from disease
1
. However, there are currently only 
51 antibiotics (including combinations) in clinical development
2
, compared to over 
830 oncology drugs in clinical trials
3
. Clostridium difficile is a Gram-positive spore-
forming anaerobic bacterium that colonises the gastrointestinal tract as a result of 
disturbance to the gut microbiota. C. difficile, which has been identified as an urgent 
threat by the Center for Disease Control and Prevention
4
, claims over 14,000 lives 
annually in the US and is an increasing concern worldwide
5, 6
. Out of the 51 
antibiotics in clinical development, only 7 have a C. difficile indication with over 50% 
of these belonging to an old antibiotic class
2
. With a less than 10% chance of any drug 
in clinical development getting to market
7
, the current Clostridium difficile-associated 
disease (CDAD) pipeline would translate to 1 drug being commercialized at best, 
highlighting the need for further research in the area and the need for continuous 
development of new and effective treatment options. Ramizol, a first-in-class non-
systemic styrylbenzene antibiotic, is in preclinical development for the treatment of C. 
difficile infections (CDI). The new class, identified using a combinatorial approach 
composed of de novo design and in silico docking, targets the mechanosensitive ion 
channel of large conductance (MscL)
8
, a highly conservative transmembrane protein 
not present in the human genome. In a hamster C. difficile colitis infection model 
using the NAP1/027 strain, animals treated with Ramizol showed survival rates of 
73% compared to 83% in the vancomycin treated group and no animals surviving in 
the untreated group; in addition, a significant reduction of spore counts in Ramizol-
treated hamsters compared to the control was found
9














shown no risk of resistance emergence in two strains of C. difficile when high inocula 
were tested at 4x and 8x MICs
9
. Here, we investigate the in vitro activity of Ramizol 
against a diverse collection of 100 clinical isolates of C. difficile, including those 
characterized for toxin production and ribotype, to determine if the antibacterial 
activity of the drug translates to other isolates and compare it’s activity to 
fidaxomicin, metronidazole and vancomycin.  
Materials and Methods 
Chemicals. Ramizol was shipped to Micromyx and stored at room temperature, 
protected from light. The solvent for the preparation of the Ramizol stock solutions 
was 100% dimethylsulfoxide (DMSO; Sigma, St. Louis, MO). The Ramizol stock 
concentration was 5,120 μg/mL. Stock preparations of fidaxomicin (purchased from 
API) and metronidazole (purchased from Sigma) were made using a DMSO:water 
mixture (5% DMSO final) at concentrations of 320 μg/mL and 2,560 μg/mL, 
respectively. Vancomycin (purchased from Sigma) stocks (2,560 μg/mL) were 
prepared in water. Stock solutions were aliquoted and stored at 4 ºC until use.  
Antimicrobial susceptibility testing. Test organisms for the assay were 100 C. 
difficile clinical isolates selected from the Micromyx collection (Table S1) as well as 
the American Type Culture Collection (ATCC) quality control organism C. difficile 
ATCC 700057. The clinical strains used were isolated in 2003, 2011, 2014, 2015 and 
2016 with the majority isolated in 2011 and 2014. Of the 100 strains used, 31% of the 
isolates came from California, 61% from Indiana, 7% from New York and 1% from 
Michigan. Toxin positive strains formed 64% of the isolates (48% of which belong to 
a known ribotype), toxin negative strains formed 28% of the isolates and 8% were not 
identified.  














accordance with guidelines from the Clinical and Laboratory Standards Institute
10, 11
 
with the exception that Reinforced Clostridial Medium was used as the primary test 
medium as previously reported
9
. After preparation of plates containing serially diluted 
Ramizol or comparator, plates were transferred into a Bactron II anaerobic chamber 
(Sheldon Manufacturing Inc., Cornelius, OR) and allowed to reduce for 1 – 2 hr 
before inoculating. After inoculation, plates were incubated in BD Gaspak EZ 
Anaerobe containers at 35 ºC for 46-48 hr. The MIC was read and recorded as the 
lowest concentration of drug that inhibited visible growth of the organism.  
Results 
The drug stocks of fidaxomicin, vancomycin, and metronidazole used in the assay 
were validated by MICs observed with C. difficile ATCC 700057 in supplemented 
Brucella agar, which were within the established CLSI QC range (results not shown). 
The MIC results observed for Ramizol and the comparators are summarized in Table 
1. For Ramizol, the MIC range was ≤0.12 – 8 μg/mL while for fidaxomicin, 
vancomycin and metronidazole, the MIC range was wider. Eight isolates were 
resistant to vancomycin and two to metronidazole, using the EUCAST ECOFF 
breakpoints (2 g/ml for both). A breakpoint has not been defined for fidaxomicin. 
Two of the vancomycin-resistant isolates were noted to be much less susceptible to 
fidaxomicin (MIC > 8 g/ml) but were susceptible to Ramizol with MICs of 2 g/ml 
and 4 g/ml. The two strains resistant to metronidazole were susceptible to Ramizol 
with an MIC of 2 g/ml and the remaining six strains, which were resistant to 
vancomycin were susceptible to Ramizol at concentrations from 1 to 8 g/ml, 
concentrations similar to the MICs of Ramizol against antibiotic sensitive C. difficile 
strains (Table S1) and MICs against toxin-positive and toxic-negative isolates (Table 














Table 1. Summary of the in vitro activity of Ramizol and comparators in 
reinforced Clostridial Medium by broth microdilution against clinical C. difficile 
isolates (N=100) 
 Ramizol Fidaxomicin Vancomycin Metronidazole 
MIC range (μg/mL) ≤0.12 – 8  ≤0.008 - >8 ≤0.06 - 32 ≤0.06 - >64 
MIC range of toxin-
positive isolates (n = 64) 
≤0.12 – 8 ≤0.008 - >8 0.12 - 32 ≤0.06 - 1 
MIC range of toxin-
negative isolates (n = 36) 
≤0.12 – 8 ≤0.008 - >8 ≤0.06 - 32 ≤0.06 - >64 
MIC50 (μg/mL) 2 0.015 0.5 0.12 
MIC90 (μg/mL) 4 0.03 2 0.25 
 
The resulting MIC distribution is shown in Figure 1, and a line listing of results by 
isolates is shown in Table S1. The MIC distributions of fidaxomicin and to a lesser 
extent metronidazole are positively skewed, while vancomycin is negatively skewed, 
and Ramizol displays more of a normal distribution. Ramizol activity was not notably 
impacted by the type of isolate, with similar MICs across the evaluated ribotypes and 
against toxin-positive isolates relative to toxin-negative isolates, Table 1. This was 
the same for the other drugs tested with the exception of metronidazole, which had 
higher MICs against toxin-negative isolates. Clinical isolates with reduced 
susceptibility to fidaxomicin, metronidazole or vancomycin, did not differ from the 
















Figure 1. MIC distribution of Ramizol, vancomycin, metronidazole and fidaxomicin 




C. difficile infections remain the primary cause of diarrhoea from antibiotic 
administration, and are a serious problem in healthcare settings and the community. 
Other factors such as the use of proton pump inhibitors and the use of anticancer 
drugs also increase the risk of CDI
12
. Severity of the infection ranges from mild 
diarrhoea to severe life-threating pseudomembraneous colitis and toxic megacolon, an 
inflammation of the colon resulting from the overgrowth of C. difficile. C. difficile 
toxin-producing ribotypes carry virulence factors (toxins A and B) that stimulate 
epithelial tissue damage and inflammation in the host
13
. Some strains such as 
BI/NAP1/027 and ribotype 078 isolates produce an additional binary toxin which is 
prevalent in strains associated with severe disease
14
. The antibiotic of choice for the 
treatment of mild C. difficile infections remains metronidazole, mostly cost-driven, 
while vancomycin is the antibiotic of choice for severe infections
5, 12, 14














cases however, they are not effective and do not prevent a relapsing infection. In 
addition, almost 100% of metronidazole is absorbed
14
 from the intestine, with faecal 
concentrations of the drug at less than 10 μg/mL
12
. This concentration is below the 
MIC of some resistant isolates; the low faecal concentration is thought to contribute 
towards the development of resistance in C. difficile
12, 14
. Fidaxomicin, approved in 
2011 for the treatment of CDI, is selective against C. difficile over other gut microbes, 
and has been more successful than vancomycin in reducing relapse caused by strains 
other than PCR ribotype 027
5, 15
, an isolate with an elevated fidaxomicin MIC (16 
μg/mL). However fidaxomicin still fails in approximately 1 out of 8 patients treated 
with the antibiotic
16
 and in clinical trials, elevated MICs were observed
17
. Antibiotic 
resistance is still rare in C. difficile, but does occur. In a study investigating the in 
vitro susceptibility of fidaxomicin, metronidazole and vancomycin against 398 strains 
of C. difficile clinical isolates from 73 hospitals in 26 European countries, no 
resistance to any of the antibiotics tested was reported
6
. Susceptibility data compiled 
from a number of studies listed MIC ranges between 0.16 – 32 μg/mL, 0.016 – 16 
μg/mL and <0.008 – 2 μg/mL for metronidazole, vancomycin and fidaxomicin, 
respectively
18
. While a link between failure of treatment in CDI patients and elevated 
MICs is unestablished, it is a contributing factor among others such as the 
pharmacokinetics of the drug, the health of the microbiota and the absence of 
recurrence of CDI after antibiotic excretion
12
. Failure of CDI therapy in these cases 
requires the development of novel antibiotics for C. difficile infections ensuring that 
new drugs are active against isolates with reduced susceptibility to antibiotics in 
current use. In our study, Ramizol was fully active against isolates with reduced 
susceptibility to fidaxomicin, metronidazole and vancomycin, suggesting that pre-














activity. This was also previously observed in other species where Ramizol 
maintained activity against resistant isolates
8
. The clinical implication of narrower 
MIC range for Ramizol is better control over the dose (and cost) required to achieve a 
successful clinical outcome. Considering the fast spreading nature of C. difficile, 
resistance emergence is a real concern, and with few treatment options currently 
available for CDI, there is a clear need for the development of new and effective 
treatments. Ramizol is a promising investigational drug for CDI that is advancing to 
first-in-man clinical trials. Future studies will include evaluation of susceptibility to 
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 Ramizol a first-in-class styrylbenzene antibiotic is effective against 100 
strains of C. difficile 
 
 C. difficile clinical isolates show resistance to vancomycin and 
metronidazole 
 
 Vancomycin-resistant strains show elevated MICs (> 8 μg/mL) in the 
presence of fidaxomicin 
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